
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is supported by a best-in-class protein reagents franchise and a diagnostics/genomics portfolio that benefits from durable demand in pharma, biotech, academic, and diagnostic markets, with ~20% of sales tied to private/SMID biotech and ~15% exposure to cell therapy after Wilson Wolf. The company also appears well positioned for a funding recovery, as biotech VC, IPO, and secondary activity more than tripled year-to-date year over year through April, which should eventually support demand for its consumables and instruments. Fundamentally, self-help actions such as divesting Exosome Diagnostics and consolidating brands from 10 to 3 should aid margins, while the planned Wilson Wolf acquisition adds growth, high EBITDA margins, and a strategic fit in cell therapy manufacturing.
Bears say
Bio-Techne is facing a negative setup because its core life-science tools markets have still not normalized, and the company has already suffered years of false starts in demand recovery. Its protein sciences business, which drives about 75% of revenue, is exposed to wet-lab research demand that could be structurally pressured if software and AI reduce experiment volume, while diagnostics and genomics also face execution and adoption risk. Competitive pressure is intensifying as key rivals like PeproTech, Abcam, and BioLegend have been acquired by larger players, and with cell therapy tied to roughly 15% of sales, any disappointment there could amplify multiple compression and share loss concerns.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares